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Pertussis, an acute disease of the upper
respiratory tract caused by the gram-negative
bacillus Bordetella pertussis, lasts 6 to 8 weeks
and has three clinical stages. The initial
(catarrhal) stage resembles a common cold with a
mild cough. The second (paroxysmal) stage is
characterized by episodes of repetitive coughing
during a single expiration, followed by a sudden
inspiration that generates the typical “whoop.”
The final (convalescent) stage, which lasts 1 to 2
weeks, marks a decrease in the severity and
frequency of the cough (1).
Since the introduction of routine childhood
vaccine, pertussis has been considered prevent-
able, and pertussis-associated illness and deaths
are uncommon (2). However, vaccine-induced
immunity wanes after 5 to 10 years, making the
vaccinated host vulnerable to infection (3). This
susceptibility has been described in outbreaks
of pertussis infection in highly vaccinated
populations (3-6).
A recent study by Yaari et al. showed that
infection in a vaccinated person causes milder,
nonspecific disease, without the three classical
clinical stages (7). Whooping cough is seen in
only 6% of such cases; instead, the illness is
characterized by a nonspecific, prolonged cough,
lasting several weeks to months. Because of
these atypical symptoms, pertussis infection is
underdiagnosed in adults and adolescents, who
may be reservoirs for infection of unvaccinated
infants (8-10). In a study in France, up to 80% of
infections in unvaccinated children were ac-
quired from siblings and parents, suggesting that
adults and even young siblings play a fundamen-
tal role in the transmission of pertussis (11).
We demonstrated B. pertussis infection in
fully vaccinated children ages 2-3 years and 5-6
years who had contact with an infected child.
We investigated whether younger or recently
vaccinated children may be protected from
classical clinical illness but remain susceptible to
infection and become asymptomatic carriers.
The Study
We examined the family of a 4-month-old
infant who died of pertussis in Israel, as well as
children at two day-care centers that two siblings
had attended during the infant’s illness. The two
siblings, ages 2 and 5 years, attended different
day-care centers, for ages 2-3 years and 5-6 years,
respectively. Both siblings continued to attend
the centers despite paroxysmal cough for 4 to 5
weeks. Thirty other children attended the day-
care center for the 2- to 3-year-old group. Sixteen
other children attended the center for the 5- to 6-
year-old group.
In the infant’s family, a third sibling, age 11
years, also had a paroxysmal cough of 4 to 5
weeks’ duration. The 35-year-old mother had a
3-month history of persistent cough. An 18-year-
old aunt, who took care of the infant and lived in
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Figure. Timeline of pertussis infection in children in
two day-care centers, Israel.
the same house, reported a mild respiratory
illness without paroxysmal cough. None of the
family members had a whooping episode,
cyanosis, or pneumonia (Figure).
All the children in the day-care centers had
been immunized in infancy with all four doses of
Pasteur diphtheria-tetanus toxoid pertussis
(DTP) vaccine, which includes a booster dose at
12 months of age. The Pasteur vaccine contains
1 immunization dose (ID) of purified diphtheria
toxoid, 1 ID of purified tetanus toxoid, and >4 IU
of B. pertussis. All family members of the infant
were also fully vaccinated with four doses of DTP.
The infant had received only the first dose of
vaccine at 2 months of age.
The five family members of the infant and the
46 children in the two day-care centers were
tested for B. pertussis. Two nasopharyngeal
specimens were taken with Dacron swabs
(Medical Wire, MEDECO, Corsham, UK); one
specimen was used for culture and the other for
polymerase chain reaction (PCR) testing. The
culture specimen was immediately spread on
charcoal agar plates (Hy Labs, Rehovot, Israel),
which were incubated at 37°C for 14 days. Serum
samples were also taken from every study
participant for specific testing for immunoglobulin
(Ig) M, IgA, and IgG antibodies to B. pertussis by
an enzyme immunoassay (EIA) with whole-cell
antigens (Panbio, East Brisbane, Australia) (12).
Primers for the repeated insertion sequences
were used in a semi-nested PCR assay (13-14).
The upstream primer sequence gATTCAATA
ggTTgTATgCATggTT and downstream primer
AATTgCTggACCAT TCgAgTCgACG were used
in the first PCR, which included 5 µL sample
DNA, reaction buffer (10 mM Tris-HCl, 50 mM
KCl, 1.5 mM MgCl2, 0.1% Triton X-100), 1 µM of
each primer, 200 µM deoxynucleotide
triphosphate, and 1 U Taq polymerase (Boehringer
Mannheim, Germany) in a 25-µL volume (14).
Statistical analysis was performed by the two-
tailed Fisher’s exact test.
A person with positive PCR results was
considered to have B. pertussis colonization of the
nasopharynx. A person with positive IgM serum
antibodies was considered to have had a recent
infection. There were no culture-positive results,
and nasopharyngeal aspirates were not available
from the infant. Positivity by PCR or IgM did not
indicate presence of symptoms.
Information on clinical symptoms was
obtained from each person by a detailed
questionnaire. The children in the day-care
centers were followed clinically for 8 weeks after
laboratory testing. All family members had been
treated with erythromycin before testing, but no
antibiotics were administered to the children in
the day-care centers.
Eleven percent of the children in the two day-
care centers were PCR positive, indicating
nasopharyngeal colonization: 4 (25%) of the 16 5-
to 6-year-old and 1 (3%) of the 30 2- to 3-year-old
children (p <.05). Nine (55%) 5- to 6-year-old
children were positive for serum IgM antibodies,
and 4 (25%) were IgA positive. Three (10%) of the
2- to 3-year-old children were IgM positive, and
1 (3%) had IgA antibodies. Nasopharyngeal
colonization was found more frequently in the 5-
to 6-year-old than in the 2- to 3-year-old children
(4/16 vs. 1/30, p <.05). This trend was also
constant with IgM and IgA serum antibodies (9/
16 vs. 3/30, p <.001 and 4/16 vs. 0/30, p <.01,
respectively). In the index family, four of five
members were positive by PCR, including all
three siblings of the infant and the 18-year-old
aunt. The 35-year-old mother, who was treated
with erythromycin before testing, was negative
by PCR. All five family members, including the
mother, had high levels of IgM antibodies,
indicating recent infection. The 4-month-old
infant was seronegative for all subclasses of Ig
antibodies to B. pertussis. No cultures were
grown from the three groups.
According to a modified World Health
Organization (WHO) case definition, two of the
five children colonized with B. pertussis in the
two day-care centers had the typical course of
pertussis infection, with 3 weeks of paroxysmal
cough (Table) (1). The other three children who
were positive by PCR had only a mild, nonspecific
cough during follow-up.528 Emerging Infectious Diseases Vol. 6, No. 5, September–October 2000
Dispatches
Conclusions
The effects of whole-cell pertussis vaccine
wane after 5 to 10 years, and infection in a
vaccinated person causes nonspecific symptoms
(3-7). Vaccinated adolescents and adults may
serve as reservoirs for silent infection and
become potential transmitters to unprotected
infants (3-11). The whole-cell vaccine for
pertussis is protective only against clinical
disease, not against infection (15-17). Therefore,
even young, recently vaccinated children may
serve as reservoirs and potential transmitters of
infection.
We used PCR, EIA, and culture to confirm
B. pertussis infection in two highly vaccinated
groups of children in two day-care centers. Three
(10%) of 30 2- to 3-year-old children were
seropositive for recent infection; one had
nasopharyngeal colonization and a clinical
illness that met the modified WHO case
definition. In the day-care center for the 5- to 6-
year-old group, 9 (55%) of 16 children were IgM
positive, 4 (25%) of whom had nasopharyngeal
colonization. Of these four children, three had
nonspecific cough, and only one met the modified
WHO definition for pertussis. None of the
children in our study, including those who met
the WHO definition, had been examined by a
physician before our investigation.
Children who were seropositive and re-
mained both asymptomatic and PCR negative
probably had sufficient immunity from vaccines
or natural boosters to protect them against
persistent colonization and clinical disease. Their
seropositivity could not be due to vaccine because
the children were tested more than a year after
having been vaccinated. Yet not all the children
were protected from infection and from coloniza-
tion with the bacteria. Whether a child who is
serologically or PCR positive for pertussis and is
clinically asymptomatic is a potential transmit-
ter of infection has not been established. What is
certain, however, is that vaccine-induced immu-
nity against infection does not persist throughout
adulthood. In France, booster vaccinations have
been recommended for adolescents and teenag-
ers (18). We found that immunity does not even
persist into early childhood in some cases. We
also observed that DPT vaccine does not fully
protect children against the level of clinical
disease defined by WHO. Our results indicate
that children ages 5-6 years and possibly
younger, ages 2-3 years, play a role as silent
reservoirs in the transmission of pertussis in the
community. More studies are needed to find the
immunologic basis of protection against infection
and colonization and thus an effective way to
eradicate pertussis.
Dr. Srugo is a senior lecturer and director of the Clini-
cal Microbiology and Pediatric Infectious Disease unit at
the Bnai Zion Medical Center, Haifa, Israel.
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